E-submission
Search
- Page Path
- HOME > Search
Case Study
- Cytologic Characteristics of Thymic Adenocarcinoma with Enteric Differentiation: A Study of Four Fine-Needle Aspiration Specimens
- Ah-Young Kwon, Joungho Han, Hae-yon Cho, Seokhwi Kim, Heejin Bang, Jiyeon Hyeon
- J Pathol Transl Med. 2017;51(5):509-512. Published online August 4, 2017
- DOI: https://doi.org/10.4132/jptm.2017.03.22
- 6,367 View
- 109 Download
- 5 Web of Science
- 7 Crossref
-
Abstract
PDF - Thymic adenocarcinoma is extremely rare. Although its histologic features have been occasionally reported, a lack of description of the cytologic features has hampered the prompt and accurate diagnosis of this condition. Herein, we describe the cytologic findings and histology of four aspiration cytology specimens of thymic adenocarcinoma. The specimens were obtained from primary tumors, metastatic lymph nodes, and pericardial effusions. All four specimens showed three-dimensional glandular clusters with a loss of polarity and nuclear overlapping. One specimen had extensive extracellular mucinous material. Three specimens contained tumor cells with intracytoplasmic vacuoles. While the specimen with extracellular mucin showed relatively mild cytologic atypia, other specimens exhibited more atypical cytologic changes: irregular nuclear membranes, a coarse chromatin pattern, and prominent nucleoli. The cytologic features were correlated with the histologic features in each case of enteric type thymic adenocarcinoma. The differential diagnosis included other thymic carcinomas, yolk sac tumors, and metastatic adenocarcinoma from the lung or colorectum.
-
Citations
Citations to this article as recorded by
- Case report: Primary adenocarcinoma NOS of the thymus and cytological features
Jonathan Willner, Osvaldo Hernandez, Lea Azour, Andre L. Moreira
Diagnostic Cytopathology.2023;[Epub] CrossRef - Systemic chemotherapy for unresectable or recurrent primary thymic adenocarcinoma of enteric type
Xiaofang Gao
International Cancer Conference Journal.2022; 12(1): 46. CrossRef - Thymic adenocarcinoma accompanied by type A thymoma and pulmonary minimally invasive adenocarcinoma and harboring distinct gene alterations
Yi-Wen Zheng, Lin-Lin Bai, Gui-Yang Jiang, Xu-Yong Lin, Yang Liu, Hong-Tao Xu
Medicine.2021; 100(15): e25254. CrossRef - A case report: primary thymic adenocarcinoma with enteric differentiation
Yuuki Kou, Hirokazu Tanaka, Nobuhisa Yamazaki, Hiroyoshi Watanabe, Makoto Sonobe
The Journal of the Japanese Association for Chest Surgery.2020; 34(2): 107. CrossRef - Primary thymic adenocarcinoma with an aggressive clinical course: An autopsy case showing signet ring cell‐like features
Ayako Shiono, Takashi Fujino, Kyoichi Kaira, Tomomi Kato, Masanori Yasuda, Kunihiko Kobayashi, Hiroshi Kagamu
Thoracic Cancer.2020; 11(12): 3609. CrossRef - Primary Thymic Signet Ring Cell Adenocarcinoma: A Currently Unrecognized Variant
Richard Benedict Supan Roxas, Marie Christine Fajatin Bernardo, Araceli Pacis Jacoba, Janet Lim-Dy, Anarose Cariaga Alvarado, Jasna Metovic, Laura Annaratone, Mauro Papotti
International Journal of Surgical Pathology.2019; 27(3): 315. CrossRef - Disseminated and massive tumor burden in a case of primary thymic mucinous adenocarcinoma
Hui-Wen Liu, Chih-Yi Liu, Yi-Chen Yeh
Journal of Cancer Research and Practice.2019; 6(3): 151. CrossRef
- Case report: Primary adenocarcinoma NOS of the thymus and cytological features
Brief Case Report
- Placental Mesenchymal Dysplasia with Fetal Gastroschisis
- Binnari Kim, Jiyeon Hyeon, Minju Lee, Hyewon Hwang, Yooju Shin, Suk-Joo Choi, Jung-Sun Kim
- J Pathol Transl Med. 2015;49(1):71-74. Published online January 15, 2015
- DOI: https://doi.org/10.4132/jptm.2014.12.14
- 10,523 View
- 85 Download
- 4 Web of Science
- 2 Crossref
-
PDF
-
Citations
Citations to this article as recorded by- Diagnostic Accuracy of the Partograph Alert and Action Lines to Predict Adverse Birth Outcomes: A Systematic Review
M. Bonet, O. T. Oladapo, J. P. Souza, A. M. Gülmezoglu
Obstetrical & Gynecological Survey.2020; 75(5): 269. CrossRef - Placental Mesenchymal Dysplasia
Linda M. Ernst
Journal of Fetal Medicine.2015; 02(03): 127. CrossRef
- Diagnostic Accuracy of the Partograph Alert and Action Lines to Predict Adverse Birth Outcomes: A Systematic Review
Original Articles
- PHH3 as an Ancillary Mitotic Marker in Gastrointestinal Stromal Tumors
- Yooju Shin, Jiyeon Hyeon, Boram Lee, Sang Yun Ha, Min Eui Hong, In Gu Do, Kyoung-Mee Kim
- J Pathol Transl Med. 2015;49(1):23-29. Published online January 15, 2015
- DOI: https://doi.org/10.4132/jptm.2014.10.08
- 8,562 View
- 71 Download
- 8 Web of Science
- 8 Crossref
-
Abstract
PDF
- Background
Counting mitoses is subjective and time-consuming. The adjunctive diagnostic utility of a recently reported mitotic marker, phosphohistone H3 (PHH3), was investigated in gastrointestinal stromal tumors (GISTs). Methods: We reviewed 77 GISTs for several proliferative indices. These included the mitotic count per 50 high power fields (HPFs), the immunohistochemical Ki- 67 labeling index and the immunohistochemical PHH3 mitotic index (MI). For comparison, Spearman’s rank correlation and interclass correlation coefficient were used. Results: Mitotic counts ranged from 0–138 (mean, 7.57±2.34) and the PHH3 MI ranged from 0–126 per 50 HPFs (mean, 9.61±2.27). We found a positive correlation between mitotic counts and PHH3 MI (r=0.810, p<.001). The inter-observer correlation coefficient for three participants was 0.975 for mitotic counts and 0.940 for the PHH3 MI. When using the PHH3 MI instead of mitotic counts in the Armed Forces Institute of Pathology (AFIP) stratification criteria, 10 cases were reclassified. In one patient with a mitotic count of 2 and a PHH3 MI of 6 per 50 HPFs, distant metastasis occurred. Conclusions: In GISTs, the PHH3 MI correlated adequately with mitotic counts and can be used as a useful adjunctive to count mitotic figures efficiently. -
Citations
Citations to this article as recorded by- A retrospective study on expression and clinical significance of PHH3, Ki67 and P53 in bladder exophytic papillary urothelial neoplasms
Gaoxiu Qi, Jinmeng Liu, Shuqi Tao, Wenyuan Fan, Haoning Zheng, Meihong Wang, Hanchao Yang, Yongting Liu, Huancai Liu, Fenghua Zhou
PeerJ.2023; 11: e15675. CrossRef - Loss of Slfn3 induces a sex-dependent repair vulnerability after 50% bowel resection
Emilie E. Vomhof-DeKrey, Jack T. Lansing, Diane C. Darland, Josey Umthun, Allie D. Stover, Christopher Brown, Marc D. Basson
American Journal of Physiology-Gastrointestinal and Liver Physiology.2021; 320(2): G136. CrossRef - Phosphohistone H3 (PHH3) as a surrogate of mitotic figure count for grading in meningiomas: a comparison of PHH3 (S10) versus PHH3 (S28) antibodies
Napaporn Puripat, Kongsak Loharamtaweethong
Virchows Archiv.2019; 474(1): 87. CrossRef - Gastrointestinal Stromal Tumors Risk Stratification Utilizing Phospho-Histone H3 Evaluated by Manual Counting and Computer-Assisted Image Analysis
Cao Jin, Yan Huang, Mansoor Nasim, Yihe Yang, Lili Lee
International Journal of Surgical Pathology.2019; 27(7): 706. CrossRef - The utility of phosphohistone H3 in early prediction of benign and borderline phyllodes tumor recurrence
AymenM El-Saka, MohamedA Mlees, YomnaA Zamzam
Egyptian Journal of Pathology.2019; 39(2): 402. CrossRef - Identification of Phosphohistone H3 Cutoff Values Corresponding to Original WHO Grades but Distinguishable in Well-Differentiated Gastrointestinal Neuroendocrine Tumors
Min Jeong Kim, Mi Jung Kwon, Ho Suk Kang, Kyung Chan Choi, Eun Sook Nam, Seong Jin Cho, Hye-Rim Park, Soo Kee Min, Jinwon Seo, Ji-Young Choe, Hyoung-Chul Park
BioMed Research International.2018; 2018: 1. CrossRef - Tumor Digital Masking Allows Precise Patient Triaging: A Study Based on Ki-67 Scoring in Gastrointestinal Stromal Tumors
Piotr Lewitowicz, Jaroslaw Matykiewicz, Magdalena Chrapek, Dorota Koziel, Agata Horecka-Lewitowicz, Martyna Gluszek-Osuch, Iwona Wawrzycka, Stanisław Gluszek
Scanning.2018; 2018: 1. CrossRef - The mitosis‐specific marker phosphohistone‐H3 (PHH3) is an independent prognosticator in uterine smooth muscle tumours: an outcome‐based study
Kin‐Long Chow, Ka‐Yu Tse, Ching‐Lung Cheung, Ka‐Wing Wong, Annie N Y Cheung, Richard W C Wong, Alice N H Chan, Nancy W F Yuen, Hextan Y S Ngan, Philip P C Ip
Histopathology.2017; 70(5): 746. CrossRef
- A retrospective study on expression and clinical significance of PHH3, Ki67 and P53 in bladder exophytic papillary urothelial neoplasms
- Prognostic Significance of BCL9 Expression in Hepatocellular Carcinoma
- Jiyeon Hyeon, Soomin Ahn, Jae Jun Lee, Dae Hyun Song, Cheol-Keun Park
- Korean J Pathol. 2013;47(2):130-136. Published online April 24, 2013
- DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.2.130
- 7,367 View
- 53 Download
- 18 Crossref
-
Abstract
PDF
Background BCL9 enhances β-catenin-mediated transcriptional activity regardless of the mutational status of the Wnt signaling components and increases the cell proliferation, migration, invasion, and metastatic potential of tumor cells. The goal of this study was to elucidate the prognostic significance of BCL9 protein expression in hepatocellular carcinoma (HCC) patients.
Methods We evaluated BCL9 protein expression by immunohistochemistry in tumor tissue from 288 primary HCC patients who underwent curative hepatectomy. The impact of BCL9 expression on the survival of the patients was analyzed. The median follow-up period was 97.1 months.
Results Nuclear BCL9 protein expression was observed in 74 (25.7%) of the 288 HCCs. BCL9 expression was significantly associated with younger age (p=0.038), higher Edmondson grade (p=0.001), microvascular invasion (p=0.013), and intrahepatic metastasis (p=0.017). Based on univariate analyses, BCL9 expression showed an unfavorable influence on both disease-free survival (DFS, p=0.012) and disease-specific survival (DSS, p=0.032). Multivariate analyses revealed that higher Barcelona Clinic Liver Cancer stage was an independent predictor of both shorter DFS (p<0.001) and shorter DSS (p<0.001). BCL9 expression tended to be an independent predictor of shorter DFS (p=0.078).
Conclusions BCL9 protein expression might be a marker of shorter DFS in HCC patients after curative hepatectomy.
-
Citations
Citations to this article as recorded by- The Wnt-dependent and Wnt-independent functions of BCL9 in development, tumorigenesis, and immunity: Implications in therapeutic opportunities
Minjie Wu, Heng Dong, Chao Xu, Mengqing Sun, Haojin Gao, Fangtian Bu, Jianxiang Chen
Genes & Diseases.2024; 11(2): 701. CrossRef - The role of BCL9 genetic variation as a biomarker for hepatitis C-related hepatocellular carcinoma in Egyptian patients
Eman Abd El Razek Abbas, Ahmed Barakat Barakat, Mohamed Hassany, Samar Samir Youssef
Journal of Genetic Engineering and Biotechnology.2022; 20(1): 4. CrossRef - Molecular Targets and Signaling Pathways of microRNA-122 in Hepatocellular Carcinoma
Kwang-Hoon Chun
Pharmaceutics.2022; 14(7): 1380. CrossRef - Wnt/β-Catenin Signalling and Its Cofactor BCL9L Have an Oncogenic Effect in Bladder Cancer Cells
Roland Kotolloshi, Mieczyslaw Gajda, Marc-Oliver Grimm, Daniel Steinbach
International Journal of Molecular Sciences.2022; 23(10): 5319. CrossRef - Bcl9 Depletion Modulates Endothelial Cell in Tumor Immune Microenvironment in Colorectal Cancer Tumor
Zhuang Wei, Mei Feng, Zhongen Wu, Shuru Shen, Di Zhu
Frontiers in Oncology.2021;[Epub] CrossRef - Wnt Signaling Pathway Is among the Drivers of Liver Metastasis
Ivana Samaržija
Livers.2021; 1(4): 180. CrossRef - Nuclear Expression of Pygo2 Correlates with Poorly Differentiated State Involving c-Myc, PCNA and Bcl9 in Myanmar Hepatocellular Carcinoma
Myo Win Htun, Yasuaki Shibata, Kyaw Soe, Takehiko Koji
ACTA HISTOCHEMICA ET CYTOCHEMICA.2021; 54(6): 195. CrossRef - Wnt status-dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma
Nicole Huge, Maria Sandbothe, Anna K. Schröder, Amelie Stalke, Marlies Eilers, Vera Schäffer, Brigitte Schlegelberger, Thomas Illig, Beate Vajen, Britta Skawran
Hepatology International.2020; 14(3): 373. CrossRef - Structure and function of Pygo in organ development dependent and independent Wnt signalling
Yan Shi, Xiushan Wu, Shuoji Zhu, Huanlei Huang, Jian Zhuang, Haiyun Yuan, Wuzhou Yuan, Ping Zhu
Biochemical Society Transactions.2020; 48(4): 1781. CrossRef - BCL9/BCL9L in hepatocellular carcinoma: will it or Wnt it be the next therapeutic target?
Akshata Moghe, Satdarshan P. Monga
Hepatology International.2020; 14(4): 460. CrossRef - Loss of BCL9/9l suppresses Wnt driven tumourigenesis in models that recapitulate human cancer
David M. Gay, Rachel A. Ridgway, Miryam Müller, Michael C. Hodder, Ann Hedley, William Clark, Joshua D. Leach, Rene Jackstadt, Colin Nixon, David J. Huels, Andrew D. Campbell, Thomas G. Bird, Owen J. Sansom
Nature Communications.2019;[Epub] CrossRef - Immunohistochemical Mapping of Bcl9 Using Two Antibodies that Recognize Different Epitopes Is Useful to Characterize Juvenile Development of Hepatocellular Carcinoma in Myanmar
Myat Thu Soe, Yasuaki Shibata, Myo Win Htun, Kuniko Abe, Kyaw Soe, Nay Win Than, Thann Lwin, Myat Phone Kyaw, Takehiko Koji
ACTA HISTOCHEMICA ET CYTOCHEMICA.2019; 52(1): 9. CrossRef - Low BCL9 expression inhibited ovarian epithelial malignant tumor progression by decreasing proliferation, migration, and increasing apoptosis to cancer cells
Jing Wang, Mingjun Zheng, Liancheng Zhu, Lu Deng, Xiao Li, Linging Gao, Caixia Wang, Huimin Wang, Juanjuan Liu, Bei Lin
Cancer Cell International.2019;[Epub] CrossRef - SOX7 Suppresses Wnt Signaling by Disrupting β-Catenin/BCL9 Interaction
Rong Fan, HaiYan He, Wang Yao, YanFeng Zhu, XunJie Zhou, MingTai Gui, Jing Lu, Hao Xi, ZhongLong Deng, Min Fan
DNA and Cell Biology.2018; 37(2): 126. CrossRef - Hypoxia activates Wnt/β-catenin signaling by regulating the expression of BCL9 in human hepatocellular carcinoma
Wei Xu, Wang Zhou, Mo Cheng, Jing Wang, Zhian Liu, Shaohui He, Xiangji Luo, Wending Huang, Tianrui Chen, Wangjun Yan, Jianru Xiao
Scientific Reports.2017;[Epub] CrossRef - Hepatocellular carcinoma biology predicts survival outcome after liver transplantation in the USA
Mohamed Abd El-Fattah
Indian Journal of Gastroenterology.2017; 36(2): 117. CrossRef - miR-30a acts as a tumor suppressor by double-targeting COX-2 and BCL9 in H. pylori gastric cancer models
Xuan Liu, Qing Ji, Chengcheng Zhang, Xiaowei Liu, Yanna Liu, Ningning Liu, Hua Sui, Lihong Zhou, Songpo Wang, Qi Li
Scientific Reports.2017;[Epub] CrossRef - BCL9, a coactivator for Wnt/β-catenin transcription, is targeted by miR-30c and is associated with prostate cancer progression
XIAO-HUI LING, ZHI-YUN CHEN, HONG-WEI LUO, ZE-ZHEN LIU, YING-KE LIANG, GUAN-XING CHEN, FU-NENG JIANG, WEI-DE ZHONG
Oncology Letters.2016; 11(3): 2001. CrossRef
- The Wnt-dependent and Wnt-independent functions of BCL9 in development, tumorigenesis, and immunity: Implications in therapeutic opportunities
- CHD1L Is a Marker for Poor Prognosis of Hepatocellular Carcinoma after Surgical Resection
- Jiyeon Hyeon, Soomin Ahn, Cheol-Keun Park
- Korean J Pathol. 2013;47(1):9-15. Published online February 25, 2013
- DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.1.9
- 7,123 View
- 56 Download
- 21 Crossref
-
Abstract
PDF
Background The gene for chromodomain helicase/ATPase DNA binding protein 1-like (
CHD1L ) was recently identified as a target oncogene within the 1q21 amplicon, which occurs in 46% to 86% of primary hepatocellular carcinoma (HCC) cases. However, the prognostic significance of CHD1L in HCC remains uncertain. In this study, we investigated the roles of CHD1L in the prognosis of HCC.Methods We investigated the expressions of CHD1L in tumor tissue microarrays of 281 primary HCC patients who underwent surgical resection using immunohistochemistry. Prognostic factors of HCC were examined by univariate and multivariate analyses. The median follow-up period was 75.6 months.
Results CHD1L expression was observed in 48 of the 281 HCCs (17.1%). CHD1L expression was associated with a younger age (p=0.033), higher Edmondson grade (p=0.019), microvascular invasion (p<0.001), major portal vein invasion (p=0.037), higher American Joint Committee on Cancer T stage (p=0.001), lower albumin level (p=0.047), and higher α-fetoprotein level (p=0.002). Multivariate analyses revealed that CHD1L expression (p=0.027), Edmondson grade III (p=0.034), and higher Barcelona Clinic Liver Cancer stage (p<0.001) were independent predictors of shorter disease-free survival.
Conclusions CHD1L expression might be a prognostic marker of shorter disease-free survival in HCC patients after surgical resection.
-
Citations
Citations to this article as recorded by- The validation of new CHD1L inhibitors as a therapeutic strategy for cancer
Sophia Clune, Paul Awolade, Qiong Zhou, Hector Esquer, Brock Matter, Jeffrey T. Kearns, Timothy Kellett, Damilola Caleb Akintayo, Uday B. Kompella, Daniel V. LaBarbera
Biomedicine & Pharmacotherapy.2024; 170: 116037. CrossRef - Role of pelitinib in the regulation of migration and invasion of hepatocellular carcinoma cells via inhibition of Twist1
Sewoong Lee, Eunjeong Kang, Unju Lee, Sayeon Cho
BMC Cancer.2023;[Epub] CrossRef - Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L
Brett J. Prigaro, Hector Esquer, Qiong Zhou, Laura A. Pike, Paul Awolade, Xin-He Lai, Adedoyin D. Abraham, Joshua M. Abbott, Brock Matter, Uday B. Kompella, Wells A. Messersmith, Daniel L. Gustafson, Daniel V. LaBarbera
Journal of Medicinal Chemistry.2022; 65(5): 3943. CrossRef - Diversity roles of CHD1L in normal cell function and tumorigenesis
Xifeng Xiong, Xudong Lai, Aiguo Li, Zhihe Liu, Ningfang Ma
Biomarker Research.2021;[Epub] CrossRef - Elevated serum alpha-fetoprotein levels are associated with poor prognosis of hepatocellular carcinoma after surgical resection: A systematic review and meta-analysis
Hong-Lin Chen, Yu-Hua Chen, Lin Du, Yi-Ping Song, Bin Zhu
Arab Journal of Gastroenterology.2021; 22(1): 12. CrossRef - Genome-wide scanning for CHD1L gene in papillary thyroid carcinoma complicated with type 2 diabetes mellitus
Y. Y. Kang, J. J. Li, J. X. Sun, J. X. Wei, C. Ding, C. L. Shi, G. Wu, K. Li, Y. F. Ma, Y. Sun, H. Qiao
Clinical and Translational Oncology.2021; 23(12): 2536. CrossRef - The high expression of CHD1L and its clinical significance in human solid tumors
Long Zhang, Yufen Jiang, Panpan Jiao, Xiaohong Deng, Yuancai Xie
Medicine.2021; 100(10): e24851. CrossRef - Clinical Significance of Trk Receptor Expression as a New Therapeutic Target in Hepatocellular Carcinoma
Sangjoon Choi, Sujin Park, Yoon Ah Cho, Cheol-Keun Park, Sang Yun Ha
Pathology & Oncology Research.2020; 26(4): 2587. CrossRef - Hepatocyte ploidy and pathological mutations in hepatocellular carcinoma: impact on oncogenesis and therapeutics
Taiji Yamazoe, Taizo Mori, Sachiyo Yoshio, Tatsuya Kanto
Global Health & Medicine.2020; 2(5): 273. CrossRef - First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer
Joshua M. Abbott, Qiong Zhou, Hector Esquer, Laura Pike, Travis P. Broneske, Sébastien Rinaldetti, Adedoyin D. Abraham, Dominique A. Ramirez, Paul J. Lunghofer, Todd M. Pitts, Daniel P. Regan, Aik Choon Tan, Daniel L. Gustafson, Wells A. Messersmith, Dani
Molecular Cancer Therapeutics.2020; 19(8): 1598. CrossRef - Prognostic role of chromodomain helicase DNA binding protein 1-like protein in human solid cancers
Wanwei Liu, Jiwei Xu, Caiyun Zhang
Medicine.2018; 97(29): e11522. CrossRef - CHD1L Expression Increases Tumor Progression and Acts as a Predictive Biomarker for Poor Prognosis in Pancreatic Cancer
Chuan Liu, Xiaowei Fu, Zhiwei Zhong, Jing Zhang, Haiyan Mou, Qiong Wu, Tianle Sheng, Bo Huang, Yeqing Zou
Digestive Diseases and Sciences.2017; 62(9): 2376. CrossRef - Overexpression of CHD1L is associated with poor survival and aggressive tumor biology in esophageal carcinoma
Ze-Han Liu, Qi Zhang, Yi-Jie Ding, Ying-Hui Ren, Hui-Peng Yang, Qing Xi, Ying-Nan Cheng, Guo-Lin Miao, Hong-Kun Liu, Cai-Xia Li, Wen-Qiang Yan, Yan Li, Zhenyi Xue, Lijuan Zhang, Xin-Ye Li, Chen-Long Zhao, Yurong Da, Xian-Zhong Wu, Jun-Qiang Chen, Rongxin
Oncotarget.2017; 8(43): 74178. CrossRef - CHD1L Regulates Cell Cycle, Apoptosis, and Migration in Glioma
Jie Sun, Li Zhang, Hongyu Zhao, Xiaojun Qiu, Wenjuan Chen, Donglin Wang, Na Ban, Shaochen Fan, Chaoyan Shen, Xiaojie Xia, Bin Ji, Yuchan Wang
Cellular and Molecular Neurobiology.2016; 36(4): 565. CrossRef - Expression of DBC1 is associated with poor prognosis in hepatitis virus-related hepatocellular carcinoma
Sang Yun Ha, Jeong Hoon Kim, Jung Wook Yang, Hyunsik Bae, Hae Yon Cho, Cheol-Keun Park
Pathology - Research and Practice.2016; 212(7): 616. CrossRef - The Overexpression of CCAR1 in Hepatocellular Carcinoma Associates with Poor Prognosis
Sang Yun Ha, Jeong Hoon Kim, Jung Wook Yang, Jimin Kim, Binnari Kim, Cheol-Keun Park
Cancer Research and Treatment.2016; 48(3): 1065. CrossRef - Genetic alterations in hepatocellular carcinoma: An update
Zhao-Shan Niu, Xiao-Jun Niu, Wen-Hong Wang
World Journal of Gastroenterology.2016; 22(41): 9069. CrossRef - CHD1L is a novel independent prognostic factor for gastric cancer
Z. Su, J. Zhao, G. Xian, W. Geng, Z. Rong, Y. Wu, C. Qin
Clinical and Translational Oncology.2014; 16(8): 702. CrossRef - Presence of CHD1L Over-Expression Is Associated with Aggressive Tumor Biology and Is a Novel Prognostic Biomarker for Patient Survival in Human Breast Cancer
Jiayi Wu, Yu Zong, Xiaochun Fei, Xiaosong Chen, Ou Huang, Jianrong He, Weiguo Chen, Yafen Li, Kunwei Shen, Li Zhu, Xin-Yuan Guan
PLoS ONE.2014; 9(8): e98673. CrossRef - CHD1L: a novel oncogene
Wen Cheng, Yun Su, Feng Xu
Molecular Cancer.2013; 12(1): 170. CrossRef - Expression of CHD1L in bladder cancer and its influence on prognosis and survival
Feng Tian, Feng Xu, Zheng-Yu Zhang, Jing-Ping Ge, Zhi-Feng Wei, Xiao-Feng Xu, Wen Cheng
Tumor Biology.2013; 34(6): 3687. CrossRef
- The validation of new CHD1L inhibitors as a therapeutic strategy for cancer
First
Prev
